Analysis of the Efficacy of Screening Tests in Colorectal Cancer by Faecal Occult Blood Test - Own Experience
Screening of the colon cancer seems to be important to improve the results of the surgical treatment. There are different screening programs, the most common use the fecal occult blood (FOB) tests or colonoscopy.
The aim of the study was to evaluate the results of the colon cancer screening based on the FOB test and perform the algorhytm improving the effectiveness of the screening.
Material and methods. 941 patients with the positive results of the FOB (immunochromatographic method) test were investigated. In all cases the rectosigmoidoscopy for the detection of the lower GI tract pathology was done. 312 patients were qualified to colonoscopy.
Results. Adenomatous polyps and adenocarcinomas were detected in 116 patients. There was no correlation between clinical symptoms and the colorectal cancer. The colorectal cancer was recognized statistically more common at the patients with previous detected neoplasia, in the colon and other organs, with hereditary nonpolyposis colorectal cancer and with inflammatory bowel diseases.
Conclusions. The colorectal cancer screening based on the FOB can be effective in the early recognition of the bowel malignancy. The previous questionnaire can eliminate from the FOB screening the patients without indications (previously done colonoscopy or barium enema) or with directly indications for colonoscopy.
Nowacki MP: Komentarz do: "Badanie przesie-wowe oraz badania kontrolne u osób obciążonych przeciętnym i zwiększonym ryzykiem zachorowania na raka jelita grubego. Zalecenia American Gastroenterology Association". Med Praktyczna 1998; 4: 129-31.
Korniluk J, Wcisło G, Nurzyński P et al.: Epidemiologia raka jelita grubego. Współcz Onkol 2006; 10 (3): 136.
Tappenden P, Chilcott J, Eggington S et al.: Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007; 56(5): 677-84
Guittet L, Bouvier V, Mariotte N et al.: Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56(2): 210-14.
Levi Z, Rozen P, Hazazi R et al.: A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146(4): 244-55.
Allison JE, Sakoda LC, Levin TR et al.: Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99(19): 1462-70.
Kerr J, Day P, Broadstock M et al.: Systematic review of the effectiveness of population screening for colorectal cancer. N Z Med J 2007; 120(1258): U2629.
Kewenter J, Björk S, Haglind E et al.: Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988; 62 (3): 645-51.
Hardcastle JD, Thomas WM, Chamberlain J et al.: Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989; 1(8648): 1160-64.
Kronborg O, Fenger C, Sondergaard O et al.: Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark. Scand J Gastroenterol 1987; 22 (6): 677-86.
Kronborg O, Fenger C, Olsen J et al.: Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989; 24 (5): 599-606.
Winawer SJ, Flehinger BJ, Schottenfeld D et al.: Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85 (16): 1311-38.
Hewitson P, Glasziou P, Watson E et al.: Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103(6): 1541-49.
Lee KJ, Inoue M, Otani T et al.: Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev 2007; 31(1): 3-11.
Yang KC, Liao CS, Chiu YH et al.: Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006; 13 Suppl 1: S8-13.
Chen ZJ, Kammer D, Bond JH et al.: Evaluating follow-up of positive fecal occult blood test results: lessons learned. J Healthc Qual 2007; 29(5): 16-20
Labianca R, Nordlinger B, Beretta GD et al.: Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Annals of Oncology 2010; 21 (Supplement 5): v70-v77.
Wiwanitkit V: Colonoscopy with and without Occult Blood Test Pre-Screening: Which is more Cost Effective for Implementation for Screening for Colon Cancer? Asian Pacific J Cancer Prev 2010; 11: 823-24.
Vijan S, Hwang EW, Hofer TP et al.: Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001; 111(8): 593-601.
West NJ, Poullis AP, Leicester RJ: The NHS Bowel Cancer Screening Programme - a realistic approach with additional benefits. Colorectal Dis 2008; 10(7): 708-14.
Whitlock EP, Lin J, Liles E et al.: Screening for Colorectal Cancer: An Updated Systematic Review. Rockville; Agency for Healthcare Research and Quality (US); 2008 Oct.
Zauber AG, Lansdorp-Vogelaar I, Knudsen AB et al.: Evaluating Test Strategies for Colorectal Cancer Screening - Age to Begin, Age to Stop, and Timing of Screening Intervals. A Decision Analysis of Colorectal Cancer Screening for the U.S. Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Evidence Syntheses, No. 65.2
Sieverding M, Matterne U, Ciccarello L: Gender differences in FOBT use: evidence from a large German survey. Z Gastroenterol 2008; 46 Suppl 1: S47-51.
Vernon SW, Tiro JA, Vojvodic RW et al.: Reliability and validity of a questionnaire to measure colorectal cancer screening behaviors: does mode of survey administration matter? Cancer Epidemiol Biomarkers Prev 2008; 17(4): 758-67.
Schroy PC 3rd, Glick JT, Robinson PA et al.: Has the surge in media attention increased public awareness about colorectal cancer and screening? J Community Health 2008; 33(1): 1-9.
Mandel JS, Bond JH, Church TR et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study N Engl J Med 1993; 328: 1365-71.
Mandel JS, Church TR, Ederer F et al.: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-037.
Hardcastle JD, Chamberlain JO, Robinson MH et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-77.
Jorgensen OD, Kronborg O, Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50: 29-32.
Godlewski D, Wojtyś P: Nowotwory złośliwe w Wielkopolsce. Ośrodek Profilaktyki i Epidemiologii Nowotworów 2009.
Iles-Shih L, Collins JF, Holub JL et al.: Prevalence of Significant Neoplasia in FOBT-Positive Patients on Warfarin Compared With Those Not on Warfarin. Am J Gastroenterol 2010; 105(9): 2030-34.
Banasiewicz T, Krokowicz Ł, Borejsza-Wysocki M i wsp.: Rodzinne występowanie chorób zapalnych jelita grubego oraz nowotworów złośliwych jamy brzusznej u chorych z wrzodziejącym zapaleniem jelita grubego. Pol Przegl Chir 2005; 10: 127-32.
Banasiewicz T, Krokowicz P, Grochowalski M et al.: Correlation of DNA ploidy and dysplasia in patients operated on for ulcerative colitis. Proktologia 2009; 10 (20): 108-16.
Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 Suppl 2: 1-5.
Soetikno RM, Lin OS, Heidenreich PA et al.: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56(1): 48-54.